Immune Check Point Modulator for Systemic Autoimmune Diseases

HLA-related Intrinsic protein mediateCD-02818s immune tolerance

Advantages

  • Low risk of side effect, auto antibody because of using intrinsic protein.
  • Modulates functions of only antigen-presenting cells.
  • Effect was demonstrated for systemic lupus erythematosus (SLE).

Technology

Recombinant HLA-related protein (HLA-x) for the treatment of autoimmune diseases, which can be manufactured by E-coli fermentation system.

Background

HLA family proteins are associated with immune system.  Topical administration of isoforms of HLA are proved to be effective for dermatological immune disease conditions. However, to date, there have been no successful reports on the treatment of systemic autoimmune diseases by HLAs.

The researcher has demonstrated the effectiveness of certain HLA (HLA-x) and determined its effective dosage, for the treatment of systemic disease such as systemic lupus erythematosus (SLE).   HLA-x, which does not affect cytotoxicity, is not so much expressed in normal conditions.

Data

  • Established HLA-x production system by E-coli expression.
  • Unmodified HLA-x (15µg/body) and PBS as control, were injected ip. twice/week for 12 weeks in SLE model mice.
  • Amount of anti-dsDNA antibodies after 72 days and urinary protein value (albumin/ creatinine) after 86 days were much lower in HLA-x treatment group (upper fig.).
  • H&E, PAM, PAS staining confirmed reduced infiltration of mononuclear cells and vasculitis in the kidney, as well as reduced proliferation of glomerular mesangial cells (lower Fig.).
  • HLA-x induced IL-6 and IL-10 in dendritic cells in vitro
  • Stabilized PEGylated HLA-x has been developed.
  • Proposed mechanism was confirmed by human cell analysis.

10-30

Patent/Publications

Pat. filed (No publications)

Researcher

Professor Katsumi Maenaka, Hokkaido University, Japan

Expectations

We are seeking a partner who can further stabilize and optimize the protein, and finally commercialize this technology.  Details can be disclosed under CDA.

Product No:CD-02818

Inquiry Form

Your Name (*Required)

E-Mail Address (*Required)

Company Name

Message

Following submission of your inquiry

We will contact you shortly to discuss confidentiality, materials transfer, evaluation steps, and licensing opportunities.

<Notice>

Our support is provided free of charge.
The information submitted on this form is for business development use only.

About Bionauts.jp Tech Manage Corp.
Copyright © Tech Manage Corp. All Rights Reserved.